RxDoctor Payments Data

Sylvia Nicholson, NP

Family · Tucson, AZNPI 1962711648

Payments from drug & device makers

$2,121in general payments, 2019–2025

Across 104 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$438
  • Amgen$205
  • Sumitomo Pharma America, Inc.$191
  • GSK$164
  • Radius Health, Inc.$161
  • Boehringer Ingelheim$132
  • plus $830 from 18 others

What the payments were for

  • Food & beverage$2,121100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,121 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$49,927
Medicare patients
362
Services billed
1,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban19$25,986
OzempicSemaglutide15$21,754
Atorvastatin Calcium140$1,702
Gabapentin46$1,401
Rosuvastatin Calcium69$1,257
Albuterol Sulfate HfaAlbuterol Sulfate33$730
Omeprazole36$691
Diclofenac Sodium20$654
Levothyroxine Sodium71$648
SynthroidLevothyroxine Sodium17$588
Metformin Hcl ErMetformin Hcl37$563
Losartan Potassium60$562
Fluticasone Propionate44$556
Amlodipine Besylate102$553
Duloxetine Hcl21$480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$25,98619 claims
Novo NordiskOzempic$77$21,75415 claims
AbbVieSynthroid$93$58817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →